• Aprindine hydrochloride is an antiarrhythmic agent presently undergoing clinical trials in the United States. Because of the narrow therapeutic-toxic ratio observed for aprindine, the long-term follow-up of these patients is important in determining the potential clinical effectiveness of this drug. In this report we examine our experience with 30 patients with drug-resistant arrhythmias who were discharged receiving aprindine and who were followed up for a mean period of 25 months.
(Arch Intern Med 1983;143:2131-2133)
Boris Strasberg, Darrel Prechel, Jerry Bauman, Aldo Coelho, Steven Swiryn, Robert Bauernfeind, Kenneth M. Rosen. Long-term Follow-up of Patients Receiving AprindineSafety and Efficacy. Arch Intern Med. 1983;143(11):2131–2133. doi:10.1001/archinte.1983.00350110117024